InterCure Ltd.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Alexander Rabinovich
- Full Time Employees
- 320
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 85 Medinat ha-Yehudim Street Herzliya Israel 4676670
- IPO Date
- Jan 28, 2019
- CIK
- 0001857030
- Website
- intercure.co
- Similar Companies
- Business
- InterCure Ltd. (NASDAQ: INCR; TASE: INCR) operates as a leading vertically integrated medical cannabis company outside North America, engaging in the research, cultivation, production, marketing and distribution of pharmaceutical-grade cannabis products through its wholly owned subsidiary Canndoc, Israel's largest licensed producer of Good Manufacturing Practices (GMP)-certified offerings; core products include dried cannabis inflorescences, cannabis extracts mixed with oil, and an expanding portfolio of over 40 branded SKUs such as Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars and Cookies-branded items available via dedicated pharmacy chains like Givol and licensed outlets including new Cookies Corners in Germany; the company also maintains investments in biomed sector portfolio companies and leverages a seed-to-shelf model serving medical patients primarily in Israel with international expansion into Europe and strategic positioning for global markets including potential U.S. opportunities. Founded in 1994 and headquartered in Herzliya, Israel, InterCure employs approximately 320 people and reported trailing twelve-month revenue of NIS 355.55 million as of recent data. Recent strategic developments include the September 2025 agreement to acquire Botanico Ltd. (dba ISHI) for approximately 4.9 million shares, providing access to premium U.S. cannabis genetics, AI-driven cultivation technology, brand partnerships like The Flowery and operational systems with expected closure in Q1 2026 pending regulatory approvals; the November 2025 definitive agreements with Cannasoul R&D Ltd. for an initial 28% stake (with exclusive path to 51% within two years), a joint R&D collaboration on evidence-based therapeutics and appointment of Prof. Dedi Meiri as chair of a new Scientific Advisory Board; prior moves encompass full acquisition of Cannolam Ltd. in 2023 securing Cookies international rights and 100% ownership of Israel's largest medical cannabis pharmacy network, alongside expansion of branded products and pharmacy locations to 24 sites.
InterCure Secures NIS 22 Million in Private Placement Financing Led by Leading Pharma-Focused Hedge Funds
InterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisition
InterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisition
InterCure Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash Flow
InterCure Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash Flow
InterCure Receives Nasdaq Notification Regarding Minimum Bid Requirement
InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash of NIS 43 Million
InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash¹ of NIS 43 Million
InterCure (NASDAQ:INCR) Shares Down 6.6% – Should You Sell?
Head to Head Comparison: InterCure (NASDAQ:INCR) and Jushi (OTCMKTS:JUSHF)
InterCure (NASDAQ:INCR) Shares Up 0.7% – Time to Buy?
InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation
InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow
InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow
InterCure Announces Strategic Acquisition of ISHI, Unlocking Access to Premium U.S. Cannabis Technology and Brands
InterCure Announces FY2024 Results and Provides Q1 2025 Update: Revenue of NIS 239 Million and Adjusted EBITDA of NIS 24 Million, Strong Start to 2025
InterCure Names Alexander Rabinovich as Chairman Replacing Ehud Barak
InterCure has Secured Funding of NIS 66M to support the recovery of Nir Oz Facility
Are Investors Missing The Forest? 35% Stock Drop Masks The International Potential Of This Weed Company
InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million